Three Stocks on the Rise That Could Keep Climbing

Key Points

• Abivax’s shares could rise further as it advances a candidate poised to disrupt a large market.

• Krystal Biotech’s strong financial results and deep pipeline make its prospects attractive.

• Marvell Technology has only begun tapping into the attractive market for custom AI chips.

Shares of Abivax (NASDAQ: ABVX) have surged over 1,500% in the past year, driven by promising clinical results for obefazimod, an investigational treatment for ulcerative colitis. The company plans to submit a regulatory application by the end of 2026, with potential expansion into Crohn’s disease indicated by ongoing trials.

Krystal Biotech (NASDAQ: KRYS) reported revenues of $116.4 million in Q1, a 32% increase year-over-year, primarily from its approved drug Vyjuvek for dystrophic epidermolysis bullosa. The company continues to explore its market potential, having prescribed the drug to over 90 patients across Japan, France, and Germany.

Marvell Technology (NASDAQ: MRVL) saw a record net revenue of $2.4 billion in the first quarter of fiscal year 2027, marking a 28% rise from the previous year. With 76% of revenue coming from data centers, Marvell is well-positioned to benefit from increasing demand for application-specific integrated circuits (ASICs) in the growing AI market.